Crescent Biopharma Announces First Patient Dosed In ASCEND Global Phase 1/2 Clinical Trial For Tumor Medication
Crescent Biopharma +8.50%
Crescent Biopharma CBIO | 19.52 | +8.50% |
Crescent Biopharma Announces First Patient Dosed In ASCEND Global Phase 1/2 Clinical Trial For Tumor Medication
